Skip to Main Content

Paper Details

Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.
Nat Cancer
67
2021
BCL-XL, BCL2, Cas9, Dasatinib, LCK, T, T-, T-ALL, T-ALLs, T-cell, T-cell acute lymphoblastic leukemia, dasatinib, hematological malignancy, leukemia, patient, preTCR, venetoclax
Author NameAffiliation
Guoqing DuDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital
Kristine R CrewsDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital
Kathryn G RobertsSt. Jude Children's Research Hospital
Giovanni RotiDana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School
Giovanni RotiUniversity of Parma
John EastonSt. Jude Children's Research Hospital
John EastonSt. Jude Children's Research Hospital
Jinghui ZhangSt. Jude Children's Research Hospital
Jinghui ZhangSt. Jude Children's Research Hospital
Stanley PoundsSt. Jude Children's Research Hospital
Stanley PoundsSt. Jude Children's Research Hospital
Mary V RellingDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital
Steven M KornblauThe University of Texas MD Anderson Cancer Center
William E EvansSt. Jude Children's Research Hospital
Charles G MullighanSt. Jude Children's Research Hospital
Kimberly StegmaierDana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School
Kimberly StegmaierThe Broad Institute of MIT and Harvard
Kimberly StegmaierDana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School
Kimberly StegmaierThe Broad Institute of MIT and Harvard
William E EvansDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital
  • 1 - 20

Datasets

Release 1.2